Breaking Barriers: IBN Joins Forces with Sustain SoCal as Media Sponsor for Upcoming ESG Event

IBN Collaborates with Sustain SoCal as Media Sponsor for ESG Forum LOS ANGELES, Sept. 21, 2023 (GLOBE NEWSWIRE) — via IBN — IBN (“InvestorBrandNetwork”), an innovative corporate communications firm and content distributor, is pleased to announce its collaboration with Sustain Southern California (“Sustain SoCal”) as the media sponsor for its upcoming ESG Forum. This in-person…

Read More

Breaking Records: The Fremont Company’s Philanthropic Initiative Supports Local Ohio Communities for Six Consecutive Years

The Fremont Company’s Philanthropic Fund-Raising Initiative Breaks Six Year Record in Supporting Local Ohio Communities FREMONT, Ohio, Sept. 21, 2023 (GLOBE NEWSWIRE) The Fremont Company, a food manufacturer located in Fremont, Ohio since 1905, is proud to announce its “Fremont Cares” initiative has set a program record, raising $3,200 to support local school lunch programs…

Read More

Act Now: Don’t Miss the Deadline for the Class Action Lawsuit Against Leslie’s Inc. (LESL)

The Impact of Class Action Lawsuits on Investors Understanding the Deadline for Filing a Lead Plaintiff Motion Investors Beware: Time is Running Out As the deadline approaches for filing a lead plaintiff motion in the class action lawsuit against Leslie’s, Inc., investors need to be aware of the potential impact on their investments. Glancy Prongay…

Read More

Get Excited: China NMPA Grants Priority Review for Golidocitinib in Treating R/R PTCL!

Welcome to the World of Innovative Medicine! Breaking News: Exciting Developments in the Field of Medical Research Shanghai, Sept. 21, 2023 – Dizal’s Golidocitinib Receives Priority Review Status Hey there, health enthusiasts and curious minds alike! Today, we bring you some thrilling news from the realm of biopharmaceuticals. Dizal, a leading innovator in the healthcare…

Read More

FDA Grants Orphan Drug Designation to Immix Biopharma’s NXC-201 for AL Amyloidosis Treatment: A Victory for Patients

FDA Grants Orphan Drug Designation to Immix Biopharma’s NXC-201 for AL Amyloidosis Treatment: A Victory for Patients The News We’ve Been Waiting For It’s official – the U.S. Food and Drug Administration has granted Orphan Drug Designation to Immix Biopharma’s NXC-201 for the treatment of Amyloid Light Chain (AL) Amyloidosis. This is a major victory…

Read More

UK’s FCA Issues Final Warning as Crypto Regulation Deadline Approaches: A Vital Update for Cryptocurrency Enthusiasts

UK’s FCA Issues Final Warning as Crypto Regulation Deadline Approaches: A Vital Update for Cryptocurrency Enthusiasts Description As the 8 October 2023 deadline approaches for activating the new financial promotions regime for digital assets, the UK’s Financial Conduct Authority (FCA) issued its last advisory warning today (Thursday), urging crypto companies targeting UK consumers to brace…

Read More

eToro Expands its Presence in the EU with New CySEC Crypto License

eToro’s Global Regulatory Standing: A Multinational Approach to Compliance eToro Gains Approval for CySEC CASP Registration eToro, the multi-asset investing platform, has announced today (Thursday) the approval of its application for registration under the CySEC CASP (Crypto Asset Service Provider) Register. This significant development marks a milestone for eToro’s global regulatory standing, allowing the platform…

Read More